The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 35, No. 12, pp. 1578-1583. DOI 10.1345/aph.1A031
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Csako, G
Right arrow Articles by Pucino, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Csako, G
Right arrow Articles by Pucino, F


Research Articles

Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders

G Csako, NJ McGriff, P Rotman-Pikielny, NJ Sarlis, and F Pucino

OBJECTIVE: To describe a patient with primary hypothyroidism in whom ingestion of levothyroxine with calcium carbonate led to markedly elevated serum thyrotropin concentrations. CASE SUMMARY: A 61-year-old white woman with primary hypothyroidism, systemic lupus erythematosus, celiac disease, and history of Whipple resection for pancreatic cancer was euthyroid with levothyroxine 175-188 micrograms/d. After taking a high dose of calcium carbonate (1250 mg three times daily) with levothyroxine, she developed biochemical evidence of hypothyroidism (thyrotropin up to 41.4 mU/L) while remaining clinically euthyroid. Delaying calcium carbonate administration by four hours returned her serum thyrotropin to a borderline high concentration (5.7 mU/L) within a month. Serum concentrations of unbound and total thyroxine and triiodothyronine tended to decrease, but remained borderline low to normal while the patient concomitantly received levothyroxine and calcium carbonate. DISCUSSION: Concomitant administration of levothyroxine and calcium carbonate often results in levothyroxine malabsorption. While in most patients the clinical consequences of this interaction, even with prolonged exposure, are relatively small, overt hypothyrodism may develop in patients with preexisting malabsorption disorders. However, as the current case illustrates, the clinical manifestations of the initial levothyroxine deficit may not always be apparent and, of all usual laboratory thyroid function tests, only thyrotropin measurement will reliably uncover the exaggerated levothyroxine malabsorption. CONCLUSIONS: Decreased absorption of levothyroxine when given with calcium carbonate may be particularly pronounced in patients with preexisting malabsorption disorders. Once recognized, a change in drug administration schedule usually minimizes or eliminates this interaction.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
S. Checchi, A. Montanaro, L. Pasqui, C. Ciuoli, V. De Palo, M. C. Chiappetta, and F. Pacini
L-Thyroxine Requirement in Patients with Autoimmune Hypothyroidism and Parietal Cell Antibodies
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 465 - 469.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
J. Boullata
Natural Health Product Interactions with Medication
Nutr Clin Pract, February 1, 2005; 20(1): 33 - 51.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.